BACKGround
Proof of concept developed by Univercells
The NevoLine™ sIPV platform was initially designed and developed by Univercells as part of a $12M Grand Challenges grant awarded by the Bill & Melinda Gates Foundation to deliver affordable inactivated polio vaccine (sIPV). After two years, Univercells introduced the platform after attaining its goals of delivering a very low cost of goods for an sIPV below $0.30 per trivalent dose. Based on this first successful application, Univercells Technologies developed the new generation of the NevoLine™ biomanufacturing product family, the NevoLine™ Upstream platform.
Overcoming the economies of scale paradigm
The NevoLine™ sIPV platform proposes a disruptive approach to achieve cost-effective viral production. The technology combines principles of process intensification, chaining, and automation in self-contained modules to drastically reduce facility footprint, capital, and operational expenditures. The NevoLine™ sIPV is the proof of concept of the NevoLine™ Upstream platform.
Watch & Listen
Reinventing commercial-scale viral production
The low footprint NevoLine™ sIPV platform delivers large quantities of bulk product, rapidly building a cost-effective capacity for viral production. The platform is suited for GMP-compliant manufacture from clinical to commercial scale.
Features
Click & Learn
Proof of concept for intensified & automated virus production
Benefits
Reliability
Automated operations increasing reproducibility, in high-safety modules offering application-specific biosafety levels
Rapid Deployment
Building production capacity in new or existing facility for a rapid market access
Cost-effectiveness
Delivering large manufacturing capacities within a small footprint, drastically reducing capital and operational expenditures
